Vapotherm, a US-based medical device maker to help people breathe, has raised $29m in its series F round from a consortium including healthcare company Kaiser Permanente’s corporate venturing unit and industrial conglomerate General Electric (GE).
Alongside Kaiser Permanente Ventures and GE Asset Management were venture capital firms 3×5 Special Opportunity Fund, which led the round, Morgenthaler Venture Partners, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.
In November 2007, Vapotherm closed its E round at $11.25m from Kaiser Permanente Ventures and QuestMark Partners and previous investments have raised at least $5.25m since 2000.
More than 500,000 patients have been treated with Vapotherm high flow therapy.